Regarding the factors associated with intestinal obstruction are so widely distributed and can not be controlled in a retrospective study like this. So from this type of study it is very difficult to comments on such type of rare side effects.
The authors should clarify and discussed the following points: Sustained-release formulations of nefedipine including Procardia XL® and Adalat XL® have been mentioned here. What about other preparations like Afeditab, Nifediac etc and intestinal obstruction. Regarding the mechanism of obstruction by these formulations is mainly because of impact of the formulation in the gut and that causes mechanical obstruction. Therefore the cause of obstruction is not clear whether it is because of formulation or drug itself ? It is not very clear. The baseline characteristics of the patients that increased the risk of intestinal obstruction have not been discussed. Should discussed about other associated factors that can lead to obstruction like use of other drugs like aspirin or disease conditions like hypertension. Because all these factors can increased the risk of obstruction In the discussion the authors should also discuss their results in contrast with already published case reports or studies.
Nothing new information is added by the present study.
VERSION 1 -AUTHOR RESPONSE

Reviewer #1
Please modify the description of bowel obstruction reported in prior case reports by whether or not these were associated with therapeutic usage or not. And, also normal or abnormal anatomy needs to be discussed as a risk factor for bezoar formation. The reviewer vaguely remembers at least one of the case reports being associated with therapeutic use, but not entirely certain. Obviously, therapeutic use is much different than overdose circumstances where bezoar formation is more likely.
Response: Previous case reports describe mechanical small bowel obstruction in the setting of therapeutic use, not overdose. It is postulated that this reflects the delivery system of this popular form of long-acting nifedipine. We have revised the introduction to indicate this.
When talking about amlodipine, clarify what "formulation not associated with bowel obstruction" means, exactly?
Response: Unlike nifedipine, amlodipine has a long duration of action and does not require formulation in an extended-release matrix. We have clarified this in the revised manuscript (page 6), contrasting the half-lives of nifedipine (2 hours) and amlodipine (30 to 50 hours) to explain why amlodipine does not require a special formulation to allow once-daily dosing.
It would be helpful to know what specific products and formulations are being prescribed. I assume only a few in Canada?
Response: The Canadian product is Adalat XL and the US product is Procardia XL. We have noted this in the revised manuscript.
